Navigation Links
Separate Sets of Research Show Treatment Improved Quality of Life,,,in as Early as Three Weeks; Patient Adherence to Medication is,,,Multifactorial

ll ages, but is often diagnosed during early adulthood. The causes of this condition are unknown, but may involve heredity, infection or the immune system.

About Asacol(R) (mesalamine) Delayed-Release Tablets 400 mg

Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).

Asacol was well-tolerated in clinical studies. Overall, the incidence of adverse events with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs. 36%), abdominal pain (18% vs. 14%), eructation (16% vs. 15%), pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%).

Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol. Please visit http://www.pgpharma.com/pi/US-Asacol.pdf for full prescribing information.

About Procter & Gamble

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Actonel(R), Asacol(R), Enablex(R), Prilosec OTC(R), Metamucil(R), Fibersure(R), Align(
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
2. NIEHS Researchers Identify Enzyme Critical in DNA Replication
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
8. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
9. President Bush Ignores Americas Plea for Support of Stem Cell Research
10. Researchers Discover Gene For Rare Skin Disorder
11. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
Post Your Comments:
(Date:9/3/2015)... 3, 2015 About dry eye syndrome Dry ... to deficient tear production or quick tear evaporation or ... types: aqueous tear deficient dry eye and evaporative dry ... do not produce enough tears, whereas meibomian gland dysfunction ... to slow tear evaporation and maintain tear stability. The ...
(Date:9/3/2015)...  WellCare Health Plans, Inc. (NYSE: WCG ) ... president and chief financial officer, is scheduled to present ... Wednesday, September 9, 2015, at 9:25 a.m. Eastern time. ... addition, a replay of the webcast will be available ... live broadcast and the replay will be available on ...
(Date:9/3/2015)... DUBLIN and ALISO VIEJO, ... plc (NYSE: AGN ), a leading global ... stage medical device company focused on developing ocular ... glaucoma, today announced that they have entered into ... in an all-cash transaction.  Under the terms of ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... N.C., Dec. 8 AstraZeneca (NYSE: AZN ... a Phase IIb clinical trial of AZD3480 (TC-1734) conducted ... as the HALO trial. , , ... for statistical significance on the primary endpoints, improvement on ...
... with Poorest Prognoses , , ... today announced data from a Phase II trial evaluating a ... myeloid leukemia (AML), the most common form of leukemia. ... limited options due to comorbidities and are typically considered ineligible ...
Cached Medicine Technology:AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 2AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 4Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 2Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 3Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 4
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law ... De La Paz. , Schmidt National Law Group, a leading firm in mass-tort ... California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Products Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements ... handling rules constantly evolving in the consumer goods industry, it can be difficult ...
(Date:9/4/2015)... ... ... “Getting away from the daily stressors and distractions of life may be ... says Jean Claude Wietzel, general manager at Four Seasons Resort Maui at Wailea. ... Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, has announced ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat ... at the 2015 symposium are doctors and researchers at the top of their ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... comparison to settlements under the Stark physician self-referral law. “Stark Law DOs ... webinar from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2
... , , ARMONK, N.Y., July 29 ... today that St. Elizabeth Healthcare is connecting hospitals, clinics ... medical records to improve patient care and lower costs. , , ... , Today, only 1.5 percent of U.S. hospital systems have a ...
... , SAN DIEGO, July 29 CareFusion ... planned spinoff from Cardinal Health, today issued the following update regarding ... On June 12, 2009, the company sent an urgent ... potential risks identified with the Alaris System. The affected devices ...
... , FLEMINGTON, N.J., July 29 A new national study ... revealed that doctors, level of concern has steadily increased over the past ... ) , , The study was conducted ... H1N1 virus and the potential risk and impact it will have on ...
... Discovery paves way for better therapies for some blood cancer ... The sequencing of the first three multiple myeloma whole genomes ... will lead to a better understanding of this form of ... The analysis of DNA from more than 50 patient samples ...
... British study finds no better nutrient value than in conventionally ... Food that beckons from the organic aisles of grocery stores ... the rest of supermarket shelves. , According to a British ... and conventionally produced foods have about the same nutrient content, ...
... ... manage and share , ... Skokie, Ill. (Vocus) July 29, 2009 -- Tabyat Partners, LLC. ( www.tabyat.com ), ... of its Web-based communication portal iluvmydoc.com™ ( www.iluvmydoc.com ). The site offers interactive services ...
Cached Medicine News:Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 2Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 3Health News:CareFusion Issues Update Regarding Previously Disclosed June 12, 2009 Recall of the Alaris(R) System 2Health News:CareFusion Issues Update Regarding Previously Disclosed June 12, 2009 Recall of the Alaris(R) System 3Health News:Physicians' Level of Concern for H1N1 Swine Flu Steadily Increases 2Health News:Physicians' Level of Concern for H1N1 Swine Flu Steadily Increases 3Health News:Multiple Myeloma Genome Unlocked 2Health News:'Organic' May Not Mean Healthier 2Health News:'Organic' May Not Mean Healthier 3Health News:Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors 2
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
Medicine Products: